12 results about "Uric acid excretion" patented technology

The invention discloses a siraitia grosvenorii instant coffee beverage assisting in reducing uric acid and a preparation method thereof, and belongs to the technical field of food based on the theory of homology of medicine and food. The coffee beverage is composed of instant coffee powder, a compound sweetening agent, coconut milk powder, milk powder and composite herbal powder in a specific proportion. The compound herbal powder is composed of poria cocos, peach kernels, dried tangerine or orange peel and momordica grosvenori which are selected from a medicinal and edible substance catalog. The herbal active ingredients and a coffee system are deeply fused by optimizing an extraction process, the dual regulation effects of inhibiting xanthine oxidase and promoting uric acid excretion are synergistically exerted, and the technical contradiction that common caffeine possibly affects uric acid excretion is effectively solved. The zebra fish in-vivo experiment proves that the level of uric acid can be remarkably reduced (Plt: 0.001), the improvement rate is as high as 17.63%, and a safe and effective daily diet intervention scheme is provided for people with hyperuricemia while the coffee flavor and convenience are provided.

The application discloses application of tomato saponin in preparation of a uric acid reducing composition and belongs to the technical field of biological medicine. The uric acid reducing composition comprises 80-240 parts of tomato saponin, 50-120 parts of momordica charantia saponin, 25-100 parts of fruit and vegetable extract, 10-20 parts of schizonepeta turczanovii extract, 10-20 parts of terminalia catappa leaf extract and 40-100 parts of soluble dietary mixture. Animal experiment verification shows that the composition can effectively reduce blood uric acid level and improve kidney function through the synergistic effect of multi-target points such as inhibition of uric acid synthesis, promotion of uric acid excretion, anti-inflammatory kidney protection and metabolic regulation, and a safe and efficient solution is provided for hyperuricemia.

The present invention relates to dihydroquinazolinone compound, a preparation method therefor, and a use thereof. The dihydroquinazolinone compound has an excellent inhibitory effect on GLUT9, can effectively inhibit GLUT9 activity so as to promote uric acid excretion, thereby achieving a uric acid lowering effect, and can be used for treating diseases related to GLUT9 activity or expression. The dihydroquinazolinone compound or a pharmaceutically acceptable salt thereof has no obvious toxicity to organs, can significantly reduce kidney damage caused by hyperuricemia, and alleviates gout symptoms.

This invention discloses a uric acid-lowering drug composition, which comprises one or more of the following: levocarnitine, levocarnitine derivatives, pharmaceutically acceptable salts of levocarnitine or its derivatives, glucocorticoids, colchicine, nonsteroidal anti-inflammatory drugs, IL-1β inhibitors, drugs that inhibit uric acid production, drugs that promote uric acid excretion, and uricase. The composition has the effects of lowering uric acid, protecting liver and kidney function, and inhibiting leukopenia.

The application discloses a composition with a function of reducing uric acid and a preparation process thereof, which is prepared from the following raw materials in parts by weight: 10-30 parts of chicory, 5-20 parts of gardenia, 5-15 parts of mulberry leaves, 5-15 parts of radix puerariae, 10-20 parts of coix seed, 5-15 parts of poria cocos, and 2-8 parts of licorice root. The application has the beneficial effects that: the seven kinds of medicine and food homologous medicinal materials such as chicory and gardenia are scientifically matched, uric acid is reduced through the double ways of inhibiting xanthine oxidase activity and promoting uric acid excretion, the animal experiment shows that the effect is better than that of the positive drug allopurinol, and the safety is high, and there is no toxic side effect; the preparation process is simple, there is no organic solvent residue, various oral dosage forms can be prepared, and the application is suitable for the auxiliary conditioning of hyperuricemia and gout.

The invention relates to the field of microorganisms. Specifically, the Hungata bacteria provided by the invention can metabolize uric acid in a culture medium, part of the bacteria can completely metabolize about 2000 [mu] g / mL of uric acid in the culture medium within 8 h, and meanwhile, in-vivo experiments also show that the content of uric acid in serum, urine and excrement of different hyperuricemia model mice can be remarkably reduced, gout is reduced, and the Hungata bacteria can be used for treating hyperuricemia. Pathological injuries of kidneys and intestinal tracts of hyperuricemia mice are relieved, organ functions are protected, pains of patients are reduced, uric acid excretion is promoted, the level of serum uric acid is reduced, intestinal barrier is maintained, intestinal environment is protected, and health of the mice is promoted. Therefore, the Hungata bacterium provided by the invention can hopefully replace or partially replace the existing compound medicine, and has a wide application prospect.

The invention relates to a dihydroquinazolinone compound as well as a preparation method and application thereof. The dihydroquinazolinone compound has an excellent inhibiting effect on GLUT9, can effectively inhibit the activity of GLUT9 so as to promote uric acid excretion, further achieves the effect of reducing uric acid, and can be used for treating diseases related to the activity or expression quantity of GLUT9. The dihydroquinazolinone compound or the pharmaceutically acceptable salt thereof has no obvious toxicity to organs, and can significantly reduce renal injury caused by hyperuricemia and relieve gout symptoms.

The invention discloses a pharmaceutical composition capable of regulating and reducing uric acid and balancing internal secretion as well as a preparation method and application of the pharmaceutical composition. The pharmaceutical composition comprises a bifunctional fusion polypeptide XUR-01 and an IL1beta TNF alpha bispecific monoclonal antibody. The fusion polypeptide is formed by sequentially connecting a xanthine oxidase inhibition domain, a GLUT9 transporter inhibition domain and an endocrine regulation domain in series through flexible connecting peptides, and the complete sequence of the fusion polypeptide is shown as SEQ ID NO: 1. The sequences of variable regions of a heavy chain and a light chain of the bispecific antibody are respectively shown as SEQ ID NO: 2 and SEQ ID NO: 3. The preparation synchronously realizes comprehensive effects of inhibiting generation of uric acid, promoting excretion of uric acid, neutralizing key inflammatory factors and regulating endocrine balance through a multi-target synergistic mechanism, and shows a treatment effect obviously superior to that of a single-target drug and good safety in treatment of hyperuricemia and related metabolic disorders. The invention overcomes the defects of single effect and large side effect of the existing medicine, and can be used for treating hyperuricemia with endocrine disorder, kidney injury or inflammation related diseases.

The invention discloses application of an AKK PROBIO strain in preparation of uric acid lowering drugs, and belongs to the technical field of microorganisms. Effective methods for treating hyperuricemia with small side effects in the prior art are still limited. In order to solve the problem, the invention provides an AKK PROBIO strain, and the preservation number of the AKK PROBIO strain is CGMCC (China General Microbiological Culture Collection Center) No.20955. The bacterium can obviously reduce the serum uric acid level of a hyperuricemia mouse, the curative effect of the bacterium is derived from a multi-system synergistic effect mechanism, the intestinal-renal axis steady state can be recovered, and hyperuricemia is improved through the following four key ways: (1) inhibiting uric acid biosynthesis; (2) the excretion of kidney uric acid is enhanced; (3) inflammation and oxidative stress reaction can be relieved; and (4) reconstructing intestinal flora balance.

This invention discloses the application of aspirin eugenol ester in the preparation of drugs for improving hyperuricemia. While maintaining the pharmacological activities of aspirin and eugenol, aspirin eugenol ester shields the carboxyl group of aspirin, reducing the gastrointestinal irritation and other side effects of aspirin upon ingestion. Simultaneously, it overcomes the irritating odor and instability of eugenol, enabling it to exert therapeutic effects in improving hyperuricemia. Through multiple pathways, including inhibiting uric acid production, promoting uric acid excretion, activating antioxidant pathways, and inhibiting inflammatory and apoptotic signals, it significantly reduces serum uric acid levels in hyperuricemic rats, thereby improving hyperuricemia.

Use of the RINL gene and an antagonist thereof in the diagnosis and treatment of hyperuricemia. Use of the RINL gene or the encoded protein thereof. The RINL gene or the encoded protein thereof is: (1) used as a marker for the diagnosis, detection, or prognosis of hyperuricemia; (2) used for preparing a reagent or kit for diagnosing or detecting hyperuricemia; or (3) used for preparing a drug for preventing and / or treating hyperuricemia. RINL is an important relevant gene in the development and progression of hyperuricemia, and is also a potential treatment site for hyperuricemia. Inhibiting the expression of RINL significantly improves the ability of cells and mice to excrete uric acid.

The application belongs to the technical field of microorganisms, and particularly relates to a high uric acid relieving Paracasei postbiotic and application thereof. Lacticaseibacillus paracasei The Paracasei (Probio-37) has a preservation number of CGMCC No. 18638. The postbiotic prepared by the strain stimulates the intestinal uric acid excretion pathway through the "gut-kidney axis", reduces the SUA level, adjusts the immune homeostasis, inhibits excessive inflammatory response, enhances the intestinal barrier integrity, effectively relieves local inflammatory response caused by urate crystals, and thus improves clinical symptoms such as joint swelling and pain, and has obvious therapeutic effect on hyperuricemia.